コンテンツへスキップ
Merck
すべての画像(1)

資料

安全性情報

SML2425

Sigma-Aldrich

Manidipine hydrochloride

≥98% (HPLC)

別名:

1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid hydrchloride, 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl ester, 3-(2-(4-Benzhydrylpiperazin-1-yl)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrchloride, CV 4093 hydrchloride, CV-4093 hydrchloride, CV4093 hydrchloride, Franidipine hydrchloride, Manidipine 6300 hydrchloride

ログイン組織・契約価格を表示する
すべての画像(1)

About This Item

実験式（ヒル表記法）:
C35H38N4O6 · xHCl
CAS番号:
257288-11-2
分子量:
610.70 (free base basis)
MDL番号:
MFCD00871291
UNSPSCコード:
12352200
NACRES:
NA.77

アッセイ

≥98% (HPLC)

形状

powder

保管条件

desiccated

色

white to beige

溶解性

DMSO: 2 mg/mL, clear (warmed)

保管温度

2-8°C

生物化学的／生理学的作用

Manidipine is a dihydropyridine class calcium channel blocker (CCB) that exerits its antihypertensive activity via targeting both L-type and T-type calcium channels. In contrary to other dihydropyridines and non-dihydropyridines that mainly act as L-type CCBs, Manidipine diminishes glomerular pressure and, consequently, albumin excretion via its action against T-type channels of efferent arterioles in addition to promoting afferent arteriole dilation by blocking L-type channels. Clinically, Manidipine is as effective in lowering blood pressure as other dihydropyridines, while only Manidipine significantly reduces albuminuria and insulin resistance with less adverse effects. In obese and hypertensive individuals, Manidipine is more effective than Lercanidipine in reducing insulin resistance, while Nifedipine treatment is reported to increase insulin desensitisation.

ピクトグラム

Skull and crossbones
GHS06

シグナルワード

Danger

危険有害性情報

H301,H336

危険有害性の分類

Acute Tox. 3 Oral - STOT SE 3

ターゲットの組織

Central nervous system

保管分類コード

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

引火点(°F)

Not applicable

引火点(℃)

Not applicable

適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

SML2425-VAR:
SML2425-BULK:
SML2425-5MG:
SML2425-25MG:

試験成績書（COA）

製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Margarita Saiz-Satjes et al.
Future cardiology, 13(2), 143-151 (2016-11-26)
In AMANDHA trial, the addition of manidipine, but not amlodipine, in diabetic patients with uncontrolled hypertension, microalbuminuria and preserved renal function resulted in a large decrease of urinary albumin excretion (UAE) despite similar blood pressure (BP) reductions. Factors associated with
H Nakaya et al.
European journal of pharmacology, 146(1), 35-43 (1988-01-27)
The effects of CV-4093, a new dihydropyridine derivative, on isolated cardiovascular tissues were compared with those of several dihydropyridine and non-dihydropyridine calcium antagonists. CV-4093 effectively inhibited the contractions induced in canine femoral arteries by high [K+]0 and Bay K 8644
K Okabe et al.
The Journal of pharmacology and experimental therapeutics, 243(2), 703-710 (1987-11-01)
Effects of CV-4093, a newly synthesized dihydropiridine type of Ca antagonist, on membrane currents in enzymatically dispersed single smooth muscle cells of the rabbit main pulmonary artery were investigated using the single electrode voltage clamp method. Three types of membrane
N Buset Ríos et al.
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 31(3), 268-274 (2011-03-17)
The combination of renin-angiotensin system blockers with calcium channel blockers appears to be one of the most effective options for treating hypertension and diabetes.Nevertheless, not all calcium blockers behave in the same manner. Manidipine, unlike other third-generation dihydropyridine derived drugs
Christian Ott et al.
British journal of clinical pharmacology, 75(1), 129-135 (2012-12-18)
Intraglomerular pressure is one of the main drivers of progression of renal failure. Experimental data suggest that there are important differences between calcium channel blockers (CCBs) in their renal haemodynamic effects: manidipine reduces, whereas amlodipine increases intraglomerular pressure. The aim
関連する文献をすべて表示

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら（テクニカルサービス）